Top Injectable Manufacturer in United Arab Emirates – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 3 days ago
- 9 min read
Last Updated: August 23, 2026
TL;DR: The United Arab Emirates regulates medicines through the newly created Emirates Drug Establishment (EDE), a federal authority established under Federal Decree-Law No. 38 of 2024 that took over nearly all pharmaceutical registration, import/export permitting, GMP/GDP/GCP certification and pricing functions from the Ministry of Health and Prevention (MOHAP) effective 29 December 2025. Registration through EDE runs on an ICH CTD/eCTD dossier with a UAE-specific Module 1, and the UAE also participates in the Gulf Central Committee for Drug Registration (GCC-DR), a regional harmonization mechanism under the Gulf Health Council. Beyond federal registration, products generally need separate emirate-level facility and formulary compliance — the Dubai Health Authority (DHA) in Dubai and the Department of Health – Abu Dhabi (DoH) in Abu Dhabi both run their own approval layers alongside EDE's federal marketing authorization. The UAE is not a Hague Apostille Convention member, so Indian-issued Certificates of Pharmaceutical Product and GMP certificates require full legalization — Ministry of External Affairs attestation in India, UAE Embassy attestation, then UAE Ministry of Foreign Affairs attestation locally — rather than a single apostille stamp. The 2022 India-UAE Comprehensive Economic Partnership Agreement (CEPA) includes a dedicated pharmaceutical annexure targeting expedited, roughly 90-day registration for Indian generic formulations and fast-track recognition for products already approved by reference regulators. The UAE imports an estimated 80%+ of the medicines it consumes despite a growing local manufacturing base (Julphar, Neopharma, and 35+ factories), and carries one of the world's highest diabetes burdens — 20.7% adult prevalence per the IDF Diabetes Atlas (2024). Farbe Firma, a WHO-GMP certified sterile injectable manufacturer in Gujarat, India producing 100+ injectable products under ISO Class 5 aseptic conditions and exporting to 30+ countries, supports UAE importers and institutional buyers with CTD/ACTD-ready documentation built around EDE's federal pathway and CEPA's fast-track provisions.
Key Takeaways
The Emirates Drug Establishment (EDE), a new federal authority created under Federal Decree-Law No. 38 of 2024, took over nearly all pharmaceutical regulatory functions from the Ministry of Health and Prevention (MOHAP) effective 29 December 2025 — including marketing authorizations, import/export/re-export permits, GMP/GDP/GCP certification, facility licensing, pricing and pharmacovigilance. Registration runs on an ICH CTD/eCTD dossier with a UAE-specific Module 1, and the UAE also participates in the Gulf Central Committee for Drug Registration (GCC-DR) under the Gulf Health Council, a regional harmonization mechanism covering all six GCC states. Farbe Firma structures its regulatory submissions in CTD format to match EDE's accepted dossier structure directly.
The United Arab Emirates is not a Hague Apostille Convention member — confirmed directly against the Convention's official Contracting Party list — so Certificates of Pharmaceutical Product, GMP certificates and other documents from India require full legalization: Ministry of External Affairs attestation in India, UAE Embassy attestation, then UAE Ministry of Foreign Affairs attestation locally, rather than a single apostille stamp. Partly offsetting that longer documentation chain, the India-UAE Comprehensive Economic Partnership Agreement (CEPA), in force since May 2022, includes a dedicated pharmaceutical annexure targeting expedited registration — around 90 days — for Indian generic formulations, plus fast-track recognition for products already approved by reference regulators such as the US FDA, EMA, UK MHRA, Health Canada, Japan's PMDA or Australia's TGA.
Institutional purchasing in the UAE is fragmented by emirate and provider type rather than centralized nationally: SEHA, the Abu Dhabi government hospital network, now sources largely through RAFED, a group purchasing organization recently merged under PureHealth; Dubai Health Authority (DHA) both regulates and directly operates Dubai's public hospitals; Emirates Health Services (EHS) covers the Northern Emirates under a federal supplier-registration system; and large private hospital groups — NMC Healthcare, Mediclinic and Aster DM Healthcare among them — represent a further, commercially significant buying channel alongside the public system. Manufacturers and their local partners need to plan for several parallel buying relationships rather than a single national tender desk.
The UAE carries one of the world's highest diabetes burdens — 20.7% adult prevalence (ages 20-79) per the IDF Diabetes Atlas and corroborating World Bank data for 2024 — alongside substantial obesity (roughly 28-30% of adults across recent surveys) and hypertension estimated in the low-20s to low-30s percent range depending on the study population, with ischemic heart disease accounting for over half of cardiovascular deaths. Despite a growing local manufacturing base led by Julphar and Neopharma, the UAE still imports an estimated 80%+ of the medicines it consumes, and its Jebel Ali Free Zone position as a re-export and regional distribution hub adds a further, distinct commercial dimension beyond domestic consumption alone.
Introduction: Why an Injectable Manufacturer in United Arab Emirates Must Meet Global Standards
The United Arab Emirates, home to an estimated 11.3 million people (2024, Federal Competitiveness and Statistics Centre), is a different kind of market from most in this series: a high-income healthcare system with sophisticated federal and emirate-level regulation, a major medical tourism destination, and a regional re-export hub, yet one that still imports an estimated 80%+ of the medicines it consumes and carries one of the world's highest diabetes burdens at 20.7% adult prevalence. An injectable manufacturer in United Arab Emirates has to be able to operate at that level of regulatory sophistication — working through the newly created Emirates Drug Establishment's federal registration process while also meeting Dubai Health Authority or Department of Health – Abu Dhabi requirements at the emirate level — rather than the single-authority registration pathway many other markets use.
Farbe Firma Pvt Ltd, operating from Gujarat, India as a WHO-GMP certified sterile injectable manufacturer, produces more than 100 injectable formulations inside ISO Class 5 aseptic filling suites and exports to more than 30 countries under CTD and ACTD dossier formats. Serving the UAE well means preparing an eCTD-ready dossier for EDE's federal review, understanding that emirate-level bodies like DHA and DoH layer their own compliance requirements on top of federal registration, and planning realistic timelines for the full document-legalization chain the UAE requires since it is not an Apostille Convention member. Farbe Firma builds its UAE engagement around all three realities at once, while also drawing on the India-UAE CEPA's pharmaceutical annexure wherever it can shorten the path.
What Sets a World-Class Injectable Manufacturer in United Arab Emirates Apart
Any credible injectable manufacturer in United Arab Emirates has to work through the Emirates Drug Establishment's registration pathway — the federal authority that took over marketing authorizations, import/export/re-export permits, GMP/GDP/GCP certification and pricing from the Ministry of Health and Prevention effective 29 December 2025 — which reviews ICH CTD/eCTD dossiers built around a UAE-specific Module 1 covering local-agent power of attorney, GMP certification, a WHO-format Certificate of Pharmaceutical Product, and bilingual Arabic-English labelling and artwork. The UAE's participation in the Gulf Central Committee for Drug Registration under the Gulf Health Council also means a product's regulatory story can extend across the wider GCC, not just the UAE alone, when manufacturers structure their dossiers with that regional context in mind.
Beyond federal registration, winning and keeping institutional business in the UAE means understanding that purchasing runs through several parallel channels rather than one national desk: SEHA's Abu Dhabi hospital network sources largely through the RAFED group-purchasing organization now under PureHealth; Dubai Health Authority regulates Dubai's market and directly operates its own public hospitals; Emirates Health Services covers the Northern Emirates through a federal supplier-registration system; and private hospital groups — NMC Healthcare, Mediclinic and Aster DM Healthcare among them — represent a further, commercially significant channel, particularly given the UAE's scale as a medical tourism destination that drew over 691,000 international health visitors to Dubai alone in 2023.
Quality Systems Behind Every Batch We Ship to United Arab Emirates
Every batch leaving Farbe Firma's Gujarat facility for the United Arab Emirates passes through the same analytical panel we apply globally. Identity, assay and related-substance testing run on validated HPLC and GC methods benchmarked against USP, BP, IP and EP monographs, Karl Fischer titration confirms residual moisture in lyophilized and powder-fill products, and every sterile lot undergoes sterility testing and bacterial endotoxin (LAL) testing, alongside sub-visible particulate counts, pH, osmolality and fill-volume verification. This is the certificate-of-analysis and validation documentation EDE reviewers expect within an eCTD-format dossier, and the same standard DHA and DoH evaluators look for during emirate-level formulary and facility compliance review.
Stability data is generated under ICH Q1A(R2) long-term and accelerated conditions, with photostability assessed per ICH Q1B, so shelf-life claims hold up under the UAE's extreme heat and humidity and the realities of onward regional distribution through hubs like Jebel Ali. Because the UAE is not a Hague Apostille Convention member, our regulatory team builds the full legalization chain — Ministry of External Affairs attestation in India, UAE Embassy attestation, then UAE Ministry of Foreign Affairs attestation locally — into every UAE-bound registration timeline from the outset, while structuring dossiers to take advantage of the India-UAE CEPA's fast-track provisions wherever a product qualifies.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in United Arab Emirates for Global Buyers
The UAE's disease profile creates strong, well-documented injectable demand. Diabetes affects an estimated 20.7% of adults aged 20-79 — among the highest national rates in the world and consistent with the Middle East & North Africa region's status as the IDF Diabetes Atlas region with the highest age-standardized diabetes prevalence globally — keeping insulin and metabolic injectables in sustained demand. Obesity affects roughly 28-30% of adults across recent surveys, and hypertension studies report figures ranging from the low-20s to low-30s percent depending on the population sampled, with ischemic heart disease accounting for more than half of cardiovascular deaths nationally, together sustaining strong, steady demand for cardiovascular and critical-care injectables across both the public system and the UAE's large private hospital sector.
For manufacturers and brand owners, Farbe Firma also functions as a CDMO/CMO partner, offering private-label sterile injectables built on the same WHO-GMP, ISO Class 5 platform, with CTD/ACTD-format technical files ready to support EDE registration and emirate-level compliance alike. The UAE's position as a re-export and logistics hub adds a further dimension: Jebel Ali Free Zone alone hosts more than 11,000 companies from over 140 countries, including regional headquarters for major global pharmaceutical names, and is positioned under a memorandum of understanding with the health ministry as a pharmaceutical manufacturing and export centre reaching dozens of countries across the Middle East, Africa and South Asia — a market Farbe Firma can support both directly and through UAE-based partners.
India's trade relationship with the UAE is substantial and actively deepening: the UAE was India's third-largest trading partner in FY2024-25, with Indian exports crossing USD 36.63 billion that year, and the 2022 India-UAE CEPA's dedicated pharmaceutical annexure — targeting roughly 90-day registration for Indian generics and fast-track recognition for products already approved by major reference regulators — gives Indian sterile-injectable manufacturers a genuine, treaty-backed advantage over exporters from non-CEPA countries. In practice, succeeding in the UAE means treating EDE's federal registration, DHA/DoH emirate-level compliance, and the UAE's full document-legalization requirement as one integrated timeline while actively using CEPA's fast-track provisions wherever eligible, and Farbe Firma's export team builds every UAE quote and delivery schedule around exactly that combination.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer for United Arab Emirates?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer based in Gujarat, India, operating ISO Class 5 aseptic filling lines and producing more than 100 injectable products for export to over 30 countries. Our documentation is prepared in CTD/eCTD format to support registration through the Emirates Drug Establishment (EDE), the UAE's federal pharmaceutical regulator since December 2025.
How does injectable product registration work in the United Arab Emirates?
The Emirates Drug Establishment (EDE), created under Federal Decree-Law No. 38 of 2024, took over federal drug registration, import/export permitting and GMP/GDP/GCP certification from the Ministry of Health and Prevention (MOHAP) effective 29 December 2025, reviewing ICH CTD/eCTD dossiers with a UAE-specific Module 1. Products generally also need separate emirate-level compliance — Dubai Health Authority (DHA) in Dubai or Department of Health – Abu Dhabi (DoH) in Abu Dhabi — alongside federal registration.
Do we need a local partner to sell injectables in the United Arab Emirates?
Yes. EDE registration requires a UAE-licensed local agent, and reaching institutional buyers typically means working across several channels — SEHA/RAFED-PureHealth in Abu Dhabi, Dubai Health Authority's own hospital network, Emirates Health Services in the Northern Emirates, and private hospital groups such as NMC Healthcare, Mediclinic and Aster DM Healthcare — so a partner experienced across these parallel channels matters as much as registration expertise.
Which injectables are in strongest demand in the United Arab Emirates?
Given the UAE's diabetes prevalence of 20.7% among adults — one of the highest rates in the world — insulin and metabolic injectables are in strong, sustained demand, alongside cardiovascular and critical-care injectables driven by high rates of obesity and ischemic heart disease. The UAE's large private hospital sector and significant medical tourism volumes add further demand for critical-care and specialty injectables. Farbe Firma's 100+ product range covers all of these categories.
What documentation and logistics considerations matter most for a UAE launch?
Because the UAE is not a Hague Apostille Convention member, Certificates of Pharmaceutical Product and GMP certificates from India require the full legalization chain — Ministry of External Affairs attestation, UAE Embassy attestation, then UAE Ministry of Foreign Affairs attestation locally — rather than a single apostille. The India-UAE CEPA's pharmaceutical annexure can offset some of that lead time with roughly 90-day fast-track registration for qualifying Indian generics, so building CEPA eligibility into the submission strategy from the outset is worthwhile.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments